Roche CEO out­lines new R&D strat­e­gy af­ter years of late-stage tri­al fail­ures

New Roche CEO Thomas Schi­neck­er is im­ple­ment­ing a re­fined R&D strat­e­gy for the sprawl­ing Swiss con­glom­er­ate in the wake of sev­er­al re­cent late-stage fail­ures.

The new goals aim to en­sure pipeline pro­grams can move more ef­fi­cient­ly from ear­ly-stage to late-stage, while the com­pa­ny al­so hunts for deals on drugs al­ready be­ing test­ed in hu­man tri­als, Schi­neck­er said Mon­day dur­ing Roche’s Phar­ma Day in Lon­don.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER